Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
$92.85M
Mr. Richard A. Paulson M.B.A.
442.00
Newton, MA
Nov 06, 2013
-0.65
$-1.14
1.47
3.62
-61.72%
-1.01
-0.02
-0.69
0.64
3.56
-42.02%
66.89%
Similar stocks (19)
Agios Pharmaceuticals, Inc.
AGIO
Replimune Group, Inc.
REPL
Nuvation Bio Inc.
NUVB
Monte Rosa Therapeutics, Inc.
GLUE
Mersana Therapeutics, Inc.
MRSN
Gossamer Bio, Inc.
GOSS
Generation Bio Co.
GBIO
HOOKIPA Pharma Inc.
HOOK
Acumen Pharmaceuticals, Inc.
ABOS
Nuvectis Pharma, Inc.
NVCT
X4 Pharmaceuticals, Inc.
XFOR
Assembly Biosciences, Inc.
ASMB
bluebird bio, Inc.
BLUE
CytomX Therapeutics, Inc.
CTMX
PMV Pharmaceuticals, Inc.
PMVP
Kronos Bio, Inc.
KRON
Rallybio Corporation
RLYB
Lyra Therapeutics, Inc.
LYRA
Galera Therapeutics, Inc.
GRTX
ETF Exposure (12)
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.391%
iShares Micro-Cap ETF
IWC
0.02429%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (19)
Agios Pharmaceuticals, Inc.
AGIO
Replimune Group, Inc.
REPL
Nuvation Bio Inc.
NUVB
Monte Rosa Therapeutics, Inc.
GLUE
Mersana Therapeutics, Inc.
MRSN
Gossamer Bio, Inc.
GOSS
Generation Bio Co.
GBIO
HOOKIPA Pharma Inc.
HOOK
Acumen Pharmaceuticals, Inc.
ABOS
Nuvectis Pharma, Inc.
NVCT
X4 Pharmaceuticals, Inc.
XFOR
Assembly Biosciences, Inc.
ASMB
bluebird bio, Inc.
BLUE
CytomX Therapeutics, Inc.
CTMX
PMV Pharmaceuticals, Inc.
PMVP
Kronos Bio, Inc.
KRON
Rallybio Corporation
RLYB
Lyra Therapeutics, Inc.
LYRA
Galera Therapeutics, Inc.
GRTX
ETF Exposure (12)
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.391%
iShares Micro-Cap ETF
IWC
0.02429%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%